SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : VVUS: VIVUS INC. (NASDAQ) -- Ignore unavailable to you. Want to Upgrade?

To: VLAD who wrote (16879)12/12/1998 6:25:00 PM
From: VLAD  Respond to of 23519
 
Did anybody read this article published in the British Journal of Urology in June. The findings appear to me to be very proMUSE. Note that 64% success rate without even using Actis. Only 7% had uncomfortable pain or burning as a side effect. Why was this study article never published as a Vivus press release? Well should I even ask this question?

ncbi.nlm.nih.gov



To: VLAD who wrote (16879)12/12/1998 6:47:00 PM
From: VLAD  Read Replies (1) | Respond to of 23519
 
Here are some more articles:

ncbi.nlm.nih.gov

ncbi.nlm.nih.gov

ncbi.nlm.nih.gov


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News